Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma
- PMID: 10733666
- DOI: 10.1046/j.1523-1747.2000.00925.x
Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma
Abstract
Histopathologic parameters of the primary tumor, such as Breslow's tumor thickness and Clark's level of invasion are the current basis for prognostic classifications of primary cutaneous melanoma. Once patients develop regional node metastasis, histopathologic features of the primary melanoma no longer contribute significantly to survival prediction. In this tumor stage, the extent of lymph node involvement is the main prognostic factor. This study addresses the question whether application of a highly sensitive molecular biology assay for detection of submicroscopic melanoma cells in sentinel lymph nodes may be suitable to improve melanoma staging. One hundred and sixteen patients with primary cutaneous melanoma with a total of 214 sentinel lymph nodes were enrolled. Sentinel lymph nodes were analyzed by histopathology including immunohistochemistry and by reverse transcription-polymerase chain reaction for tyrosinase. Patients were examined for tumor recurrences during a follow-up period of 19 mo (median). Disease-free survival probabilities were calculated and independent prognostic factors were determined by multivariate analysis. Using histopathology, micrometastatic nodal involvement was detected in 15 patients (13%). Of the 101 patients with histopathologically negative sentinel lymph nodes, 36 were reclassified by positive tyrosinase reverse transcription-polymerase chain reaction and 65 patients were still negative by reverse transcription-polymerase chain reaction. Recurrences were observed in 23 (20%) of 116 patients. These tumor recurrences were demonstrated in 10 patients (67%) with histopathologically positive sentinel lymph nodes, in nine patients (25%) with submicroscopic tumor cells detected by reverse transcription-polymerase chain reaction, and in four patients (6%) negative by both methods. The differences in recurrence rates were statistically significant (p = 0.01). In a multivariate analysis, histopathologic and reverse transcription-polymerase chain reaction status of the sentinel lymph node were demonstrated to be the only significant prognostic factors for predicting disease-free survival. Tyrosinase reverse transcription-polymerase chain reaction for the detection of minimal residual melanoma in sentinel lymph nodes is a powerful tool to determine patients who are at increased risk for subsequent metastasis. Moreover, a group of patients with high tumor thickness was identified by negative reverse transcription-polymerase chain reaction to be at low risk for recurrent disease. These data may have an impact on future tumor classifications of primary cutaneous melanoma.
Similar articles
-
Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients.Ann Surg Oncol. 2006 Jul;13(7):910-8. doi: 10.1245/ASO.2006.12.010. Epub 2006 May 22. Ann Surg Oncol. 2006. PMID: 16788751
-
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.Plast Reconstr Surg. 2003 Aug;112(2):486-97. doi: 10.1097/01.PRS.0000070989.23469.1F. Plast Reconstr Surg. 2003. PMID: 12900606
-
Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR.J Invest Dermatol. 2005 Mar;124(3):633-7. doi: 10.1111/j.0022-202X.2005.23633.x. J Invest Dermatol. 2005. PMID: 15737205 Clinical Trial.
-
Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma.Recent Results Cancer Res. 2001;158:137-46. doi: 10.1007/978-3-642-59537-0_14. Recent Results Cancer Res. 2001. PMID: 11092041 Review.
-
Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node.Melanoma Res. 2003 Jun;13(3):313-24. doi: 10.1097/01.cmr.0000056229.78713.7d. Melanoma Res. 2003. PMID: 12777989 Review.
Cited by
-
Issues affecting molecular staging in the management of patients with melanoma.J Cell Mol Med. 2007 Sep-Oct;11(5):1052-68. doi: 10.1111/j.1582-4934.2007.00091.x. J Cell Mol Med. 2007. PMID: 17979882 Free PMC article. Review.
-
Melanoma biomarkers: current status and vision for the future.Nat Clin Pract Oncol. 2009 Feb;6(2):105-17. doi: 10.1038/ncponc1296. Epub 2008 Dec 23. Nat Clin Pract Oncol. 2009. PMID: 19107110 Review.
-
[Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients].Hautarzt. 2003 May;54(5):440-7. doi: 10.1007/s00105-002-0453-6. Epub 2003 Jan 15. Hautarzt. 2003. PMID: 12719864 German.
-
[Sentinel node biopsy. What are the facts?].Hautarzt. 2005 May;56(5):441-7. doi: 10.1007/s00105-005-0927-4. Hautarzt. 2005. PMID: 15887051 Review. German.
-
Quantification of melanoma mRNA markers in sentinel nodes: pre-clinical evaluation of a single-step real-time reverse transcriptase-polymerase chain reaction assay.J Mol Diagn. 2004 Aug;6(3):253-9. doi: 10.1016/S1525-1578(10)60518-1. J Mol Diagn. 2004. PMID: 15269303 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical